RLMD Key Statistics, Chart & Performance
The current stock price of RLMD is 3.55 USD. In the past month the price decreased by -26.5%. In the past year, price increased by 917.19%.
RLMD Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to RLMD. When comparing the yearly performance of all stocks, RLMD is one of the better performing stocks in the market, outperforming 99.77% of all stocks.
RLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RLMD. The financial health of RLMD is average, but there are quite some concerns on its profitability.
RLMD Financial Highlights
Over the last trailing twelve months RLMD reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS increased by 37.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -377.61% | ||
| ROE | -593.47% | ||
| Debt/Equity | 0 |
RLMD Forecast & Estimates
8 analysts have analysed RLMD and the average price target is 10.2 USD. This implies a price increase of 187.32% is expected in the next year compared to the current price of 3.55.
RLMD Ownership
About RLMD
Company Profile
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Company Info
RELMADA THERAPEUTICS INC
2222 Ponce De Leon Blvd. 3Rd Floor
Coral Gables FLORIDA 10022 US
CEO: Sergio Traversa
Employees: 17
Phone: 16468763459
RELMADA THERAPEUTICS INC / RLMD FAQ
What does RLMD do?
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
What is the current price of RLMD stock?
The current stock price of RLMD is 3.55 USD. The price decreased by -9.21% in the last trading session.
Does RELMADA THERAPEUTICS INC pay dividends?
RLMD does not pay a dividend.
How is the ChartMill rating for RELMADA THERAPEUTICS INC?
RLMD has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting RLMD stock to perform?
8 analysts have analysed RLMD and the average price target is 10.2 USD. This implies a price increase of 187.32% is expected in the next year compared to the current price of 3.55.
What is the Price/Earnings (PE) ratio of RELMADA THERAPEUTICS INC (RLMD)?
RELMADA THERAPEUTICS INC (RLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.8).
What is the market capitalization of RLMD stock?
RELMADA THERAPEUTICS INC (RLMD) has a market capitalization of 260.32M USD. This makes RLMD a Micro Cap stock.